FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Medytox Solutions, Inc. [ MMMS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 11/02/2015 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 11/02/2015 | D | 200,000 | D | (1) | 0 | I | By: SS International Consulting, Ltd.(1) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Options to Purchase Common Stock(2) | $5 | 11/02/2015 | D | 100,000 | 05/30/2014 | 05/30/2018 | Common Stock | 100,000 | (2) | 0 | D | ||||
Options to Purchase Common Stock(2) | $5 | 11/02/2015 | D | 50,000 | 05/30/2015 | 05/30/2018 | Common Stock | 50,000 | (2) | 0 | D | ||||
Options to Purchase Common Stock(2) | $2.5 | 11/02/2015 | D | 100,000 | 05/30/2014 | 05/30/2018 | Common Stock | 100,000 | (3) | 0 | D | ||||
Options to Purchase Common Stock(2) | $2.5 | 11/02/2015 | D | 50,000 | 05/30/2015 | 05/30/2018 | Common Stock | 50,000 | (4) | 0 | D |
Explanation of Responses: |
1. Disposed of pursuant to merger agreement among Medytox Solutions, Inc. ("Medytox"), CollabRx Merger Sub, Inc. ("Merger Sub") and Rennova Health, Inc. ("Rennova") (f/k/a/ CollabRx, Inc.) in exchange for 81,928 shares of Rennova common stock, based upon an exchange ratio of 0.4096377408003329. SS International Consulting, Ltd. is wholly-owned by Mr. Sainsbury. |
2. Cancelled pursuant to merger agreement and related transactions among Medytox, Merger Sub and Rennova. |
3. Disposed of pursuant to merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 40,963 shares of Rennova common stock at an exercise price of $6.11 per share, based upon an exchange ratio of 0.4096377408003329. |
4. Disposed of pursuant to merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 20,481 shares of Rennova common stock at an exercise price of $6.11 per share, based upon an exchange ratio of 0.4096377408003329. |
/s/ Sebastien Sainsbury | 11/12/2015 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |